GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (STU:4LN2) » Definitions » Total Long-Term Assets

Capricor Therapeutics (STU:4LN2) Total Long-Term Assets : €6.95 Mil (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Capricor Therapeutics Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Capricor Therapeutics's Total Long-Term Assets for the quarter that ended in Mar. 2025 was €6.95 Mil.


Capricor Therapeutics Total Long-Term Assets Historical Data

The historical data trend for Capricor Therapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Total Long-Term Assets Chart

Capricor Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 4.33 6.80 7.23 6.78

Capricor Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.39 7.07 6.42 6.78 6.95

Capricor Therapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Capricor Therapeutics Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Capricor Therapeutics Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics Headlines

No Headlines